Sort   by:  
 Page size 
UnknownSustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Not available
S-EPMC8796656 | biostudies-literature
UnknownPomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Not available
S-EPMC7685974 | biostudies-literature
UnknownBenefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Not available
S-EPMC5668494 | biostudies-literature
UnknownDaratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Not available
S-EPMC7326710 | biostudies-literature
UnknownPomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Not available
S-EPMC3962162 | biostudies-literature
UnknownHealth-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Not available
S-EPMC8078427 | biostudies-literature
UnknownCorrelation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Not available
S-EPMC11347796 | biostudies-literature
UnknownComparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Not available
S-EPMC10960754 | biostudies-literature
UnknownDaratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Not available
S-EPMC8979809 | biostudies-literature
UnknownCNV Radar: an improved method for somatic copy number alteration characterization in oncology.
Not available
S-EPMC7060549 | biostudies-literature
Sort   by:  
 Page size